Recent studies show that SPRY4-IT1 acts as an oncogene in the TGCT development, while miR-302/367 and miR-371-373 clusters are highly expressed in tumor tissues and serum samples of TGCT patients [23–27]. This evidence concerns the gene SPRY4 and neoplasm.